Length of Stay (LOS) and Associated Healthcare Resource Use (HCRU) for a First Infusion of Axi-cel or Lisocel in Second Line for Large B-cell Lymphoma in France: Differences Observed From Comprehensive Hospital Databases
Author(s)
Catherine Thieblemont, MD, PhD1, Florian P. Colrat, MPH, PharmD2, Denis Caillot, MD3, Alexandre Caron, MD, PhD4, Camille Nevoret, PhD5, Elodie Torreton, MPH5, Sebastien Branchoux, MSc, PhD6, Fabien Despas, PharmD, PhD7.
1APHP, Paris, France, 2HEOR Manager, BMS, Rueil Malmaison, France, 3Institut de Cancérologie de Bourgogne, Dijon, France, 4CEMKA, Bourg La Reine, France, 5CEMKA, Bourg la Reine, France, 6Bristol Myers Squibb, RUEIL MALMAISON, France, 7Social Oncopharmacology, University Hospital Center CHU of Toulouse, Toulouse, France.
1APHP, Paris, France, 2HEOR Manager, BMS, Rueil Malmaison, France, 3Institut de Cancérologie de Bourgogne, Dijon, France, 4CEMKA, Bourg La Reine, France, 5CEMKA, Bourg la Reine, France, 6Bristol Myers Squibb, RUEIL MALMAISON, France, 7Social Oncopharmacology, University Hospital Center CHU of Toulouse, Toulouse, France.
OBJECTIVES: Since 2022, axi-cel and liso-cel have been available in France for the treatment of adult patients with large B-cell lymphoma, relapsed within 12 months after the end of first line immunochemotherapy or refractory to this first-line treatment (LBCL RR≤12). The objective of this study was to describe the stay and associated HCRU of patients hospitalized for a first infusion of axi-cel or liso-cel for LBCL RR≤12.
METHODS: A retrospective cohort study was conducted using comprehensive hospital stay databases (PMSI). Patients hospitalized for axi-cel or liso-cel infusion, with a specific second-line treatment code for LBCL RR≤12 and discharged between 01/01/2022 and 12/31/2023 (complete stay) were included. A descriptive analysis of the available patient and infusion stay characteristics, HCRU (intensive care unit (ICU), extra-DRG drugs) was conducted.
RESULTS: A total of 380 patients were included (axi-cel: n=343 - liso-cel: n=37), aged 58.7 (±13.7), and 63.2% were men. Mean LOS was 20.8 days (±9.3) for axi-cel and 16.7 days (±5.7) for liso-cel. This mean difference of 4.1 days was attributable to a shorter post-administration duration (axi-cel: 15.2 days (±8.3); liso-cel: 11.0 days (±2.5)). 13% (n=46) of patients treated with axi-cel and 3% (n=1) of patients treated with liso-cel were admitted to ICU. Non-CAR-T extra-DRG drugs were administered to 54.2% patients treated with axi-cel (n=186) and 16.2% with liso-cel (n=6). The majority were monoclonal antibodies, with 48.7% of patients treated with axi-cel (n=167) and 13.5% of patients treated with liso-cel (n=5) receiving tocilizumab or siltuximab. Immunoglobulins were administered to 5.8% (n=20) and 2.7% (n=1) of axi-cel and liso-cel patients. Only patients treated with axi-cel received fibrinogen (n=6, 1.7%) or voriconazole (n=6, 1.7%).
CONCLUSIONS: Despite the limited number of patients, a shorter LOS is observed in patients treated with liso-cel compared to those treated with axi-cel, with fewer ICU and extra-DRG drugs, a potential proxy for safety.
METHODS: A retrospective cohort study was conducted using comprehensive hospital stay databases (PMSI). Patients hospitalized for axi-cel or liso-cel infusion, with a specific second-line treatment code for LBCL RR≤12 and discharged between 01/01/2022 and 12/31/2023 (complete stay) were included. A descriptive analysis of the available patient and infusion stay characteristics, HCRU (intensive care unit (ICU), extra-DRG drugs) was conducted.
RESULTS: A total of 380 patients were included (axi-cel: n=343 - liso-cel: n=37), aged 58.7 (±13.7), and 63.2% were men. Mean LOS was 20.8 days (±9.3) for axi-cel and 16.7 days (±5.7) for liso-cel. This mean difference of 4.1 days was attributable to a shorter post-administration duration (axi-cel: 15.2 days (±8.3); liso-cel: 11.0 days (±2.5)). 13% (n=46) of patients treated with axi-cel and 3% (n=1) of patients treated with liso-cel were admitted to ICU. Non-CAR-T extra-DRG drugs were administered to 54.2% patients treated with axi-cel (n=186) and 16.2% with liso-cel (n=6). The majority were monoclonal antibodies, with 48.7% of patients treated with axi-cel (n=167) and 13.5% of patients treated with liso-cel (n=5) receiving tocilizumab or siltuximab. Immunoglobulins were administered to 5.8% (n=20) and 2.7% (n=1) of axi-cel and liso-cel patients. Only patients treated with axi-cel received fibrinogen (n=6, 1.7%) or voriconazole (n=6, 1.7%).
CONCLUSIONS: Despite the limited number of patients, a shorter LOS is observed in patients treated with liso-cel compared to those treated with axi-cel, with fewer ICU and extra-DRG drugs, a potential proxy for safety.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH157
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Genetic, Regenerative & Curative Therapies, Oncology